# Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

> **NCT02736955** · PHASE3 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 161 (actual)

## Conditions studied

- Tardive Dyskinesia

## Interventions

- **DRUG:** Valbenazine

## Key facts

- **NCT ID:** NCT02736955
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-13
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-06-30
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02736955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02736955, "Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02736955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*